Gilead Sciences blood cancer therapy trials put on hold by USFDA
The drug is an antibody treatment that blocks a type of protein, called CD47, which helps damaged cells avoid destruction by the immune system.
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies.The company will stop testing the drug, magrolimab, for all blood cancers and will review its safety across other studies such as those in patients with colon and breast cancers.Gilead gained access...
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies.
Read also: Gilead Sciences appoints Ted Love to Board of Directors
Original source link: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-hold-gileads-blood-cancer-therapy-trials-2024-02-07/#:~:text=Feb 7 (Reuters) - Gilead,patient death in some studies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd